Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANL Stock Forecast 2026-2027
$1.80
Current Price
$66.42M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ANL Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
ANL Price Momentum
+13.2%
1 Week Change
+18.4%
1 Month Change
-12.2%
1 Year Change
+26.8%
Year-to-Date Change
-34.5%
From 52W High of $2.75
+104.8%
From 52W Low of $0.88
📊 TOP ANALYST CALLS
Did ANL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Adlai Nortye is one of their latest high-conviction picks.
Latest ANL Stock Price Targets & Analyst Predictions
ANL has shown a year-to-date change of 26.8% and a 1-year change of -12.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for ANL. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANL Analyst Ratings
0
Buy
1
Hold
0
Sell
ANL Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.80
Latest ANL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 2, 2025 | HC Wainwright & Co. | Joseph Pantginis | Neutral | Downgrade | $N/A |
| Nov 11, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $9.00 |
| Oct 18, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $9.00 |
| Sep 4, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Initiates | $9.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Oct 24, 2023 | Cantor Fitzgerald | Louise Chen | Overweight | Initiates | $30.00 |
Adlai Nortye Ltd. ADR (ANL) Competitors
The following stocks are similar to Adlai Nortye based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ANL
Adlai Nortye
mkt cap
66.42M
Adlai Nortye Ltd. ADR (ANL) Financial Data
Adlai Nortye Ltd. ADR has a market capitalization of $66.42M with a P/E ratio of -1.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -139.0%.
Valuation Metrics
Market Cap
$66.42M
Enterprise Value
$199.68M
P/E Ratio
-1.1x
PEG Ratio
-5.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+22.2%
Current Ratio
1.0x
Debt/Equity
562.6x
ROE
-139.0%
ROA
-29.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Adlai Nortye Ltd. ADR (ANL) Business Model
About Adlai Nortye Ltd. ADR
What They Do
Biopharmaceutical company focused on oncology solutions.
Business Model
The company operates by developing innovative therapeutic solutions in the oncology sector, advancing a pipeline of treatments that cater to unmet medical needs in cancer therapy. It generates revenue through the commercialization of its therapies and partnerships within the biopharmaceutical industry, particularly targeting U.S. investors via its American Depositary Receipts.
Additional Information
Adlai Nortye aims to enhance patient outcomes through cutting-edge research and development, reflecting the significant global demand for advancements in cancer treatment. The ADR structure allows U.S. investors to easily access international biopharma opportunities, emphasizing the company's role in the interconnected healthcare market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
123
CEO
Mr. Yang Lu
Country
Cayman Islands
IPO Year
N/A
Website
www.adlainortye.comAdlai Nortye Ltd. ADR (ANL) Latest News & Analysis
Latest News
Quick Summary
Adlai Nortye Ltd. has signed an exclusive licensing agreement with ASK Pharm for its pan-RAS inhibitor AN9025, enhancing its focus on innovative cancer therapies.
Why It Matters
The licensing agreement for AN9025 could enhance Adlai Nortye's pipeline, attract investment, and drive potential revenue growth, influencing stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Adlai Nortye Ltd. (NASDAQ: ANL) will present at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics from October 22-26, 2025, in Boston.
Why It Matters
Adlai Nortye's presentation at a key cancer conference highlights its research progress, potentially affecting stock valuations and investor sentiment regarding its pipeline and future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Adlai Nortye Ltd. (ANL) is now considered technically oversold, indicating a potential end to the recent heavy selling pressure on its stock.
Why It Matters
ANL being technically oversold suggests potential for a price rebound, indicating a possible buying opportunity as selling pressure may be diminishing.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Adlai Nortye Ltd. (NASDAQ: ANL) will present preliminary data on its cancer therapy AN0025 at the ASCO Annual Meeting from May 31 to June 4, 2024, focusing on esophageal cancer treatment.
Why It Matters
Adlai Nortye's presentation of promising data for AN0025 at ASCO could enhance its market position and investor confidence, potentially influencing stock performance in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Adlai Nortye Ltd. (NASDAQ: ANL) has begun a Phase II clinical trial for palupiprant (AN0025) in treating rectal cancer, evaluating its use with chemoradiotherapy.
Why It Matters
The dosing of the first patient in Adlai Nortye's Phase II trial signals progress in cancer therapy development, potentially impacting the company's stock value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Adlai Nortye Ltd. Sponsored ADR (ANL) and Boston Scientific (BSX) have been compared to their sector's performance year-to-date. Further details on performance metrics were not provided.
Why It Matters
Performance comparisons reveal market positioning and trends, influencing investment decisions and potential shifts in capital allocation within the sector.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About ANL Stock
What is Adlai Nortye Ltd. ADR's (ANL) stock forecast for 2026?
Analyst forecasts for Adlai Nortye Ltd. ADR (ANL) are not currently available. The stock is trading at $1.80.
Is ANL stock a good investment in 2026?
According to current analyst ratings, ANL has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANL stock?
Price predictions from Wall Street analysts for ANL are not currently available. The stock is trading at $1.80.
What is Adlai Nortye Ltd. ADR's business model?
The company operates by developing innovative therapeutic solutions in the oncology sector, advancing a pipeline of treatments that cater to unmet medical needs in cancer therapy. It generates revenue through the commercialization of its therapies and partnerships within the biopharmaceutical industry, particularly targeting U.S. investors via its American Depositary Receipts.
What is the highest forecasted price for ANL Adlai Nortye Ltd. ADR?
Price targets from Wall Street analysts for ANL are not currently available. The stock is trading at $1.80.
What is the lowest forecasted price for ANL Adlai Nortye Ltd. ADR?
Price targets from Wall Street analysts for ANL are not currently available. The stock is trading at $1.80.
What is the overall ANL consensus from analysts for Adlai Nortye Ltd. ADR?
The overall analyst consensus for ANL is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are ANL stock price projections?
Stock price projections, including those for Adlai Nortye Ltd. ADR, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 2:09 AM UTC